Does insurance cover GLP-1 medications for weight loss? Sometimes — and the answer usually has less to do with the drug than with who bought your health plan. The same Wegovy pen can cost one person a small copay and cost their neighbor roughly $1,300+ a month at retail, purely because of what an employer wrote into a benefits contract. This guide lays out the 2026 coverage rules for commercial insurance, Medicare, and Medicaid, then walks through checking your own plan in about 20 minutes and appealing a denial. One warning up front: these rules change constantly, so treat this page as a map, not a promise.
Does Insurance Cover GLP-1 Drugs? The Short Answer
Coverage splits along one line: why the drug is prescribed. GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro) are covered by most plans. The same molecules prescribed for weight management (Wegovy, Zepbound) face exclusions, extra paperwork, or both.
| Plan type | Weight-loss GLP-1s (Wegovy, Zepbound) | Diabetes GLP-1s (Ozempic, Mounjaro) | Typical hurdles |
|---|---|---|---|
| Employer / commercial | Varies — many plans exclude weight-loss drugs | Usually covered for type 2 diabetes | Prior authorization, step therapy |
| Medicare Part D | Excluded by law for weight loss alone; Wegovy possible for heart-risk use | Covered for type 2 diabetes | Prior authorization |
| Medicaid | Varies by state | Generally covered for diabetes | State-specific rules |
| ACA marketplace | Often excluded, plan by plan | Usually covered for diabetes | Prior authorization |
Why the gatekeeping? These drugs are expensive, effective, and in enormous demand. Per the Cleveland Clinic, GLP-1 agonists mimic a gut hormone that slows stomach emptying and curbs appetite. In the STEP 1 trial, weekly 2.4 mg semaglutide produced an average 14.9% body-weight loss over 68 weeks; in SURMOUNT-1, tirzepatide reached up to 20.9% over 72 weeks at the highest dose. Results that strong, at four-figure list prices, are exactly what insurers build walls around.
Commercial Insurance: Your Employer Makes the Call
Most Americans with private coverage get it through work, and here is the part that surprises people: weight-loss drug coverage is an option employers buy, not a default. Two people with the same insurer can get opposite answers because one employer paid for the weight-management drug benefit and the other did not.
Coverage has also been a moving target. Some employers added GLP-1 benefits in recent plan years while others dropped or capped them as costs grew, so last year’s answer may not be this year’s. If your plan excludes these drugs today, it is worth asking HR whether that changes at open enrollment — employers do add the benefit, and some only when workers ask.
Even when weight-loss GLP-1s are on the formulary, expect conditions before your deductible and copay math starts. Our GLP-1 cost breakdown walks through what you actually pay once coverage kicks in.
What Prior Authorization Usually Requires
Prior authorization (PA) is near-universal for weight-loss GLP-1s. Plans commonly ask your prescriber to document:
- A BMI of 30 or higher, or 27+ with at least one weight-related condition such as high blood pressure or type 2 diabetes — the same criteria in the FDA’s Wegovy and Zepbound approvals
- Past weight-loss attempts, often including a documented diet or lifestyle program
- Step therapy in some plans: trying an older, cheaper medication first
- Renewal checkpoints — many plans require proof of roughly 5% weight loss after several months to keep approving refills
None of this is automatic. Incomplete chart notes are one of the most common reasons a first PA request fails, so make sure your prescriber has your full weight and diagnosis history before filing.
When Does Insurance Cover GLP-1s for Diabetes but Not Weight Loss?
Constantly — and it confuses everyone, because the molecules are identical. Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. What differs is the FDA-approved indication on the label: Ozempic and Mounjaro for type 2 diabetes, Wegovy and Zepbound for chronic weight management.
Insurers pay by indication, not by molecule. A plan can cover Ozempic at a low copay for a member with type 2 diabetes and deny Wegovy for weight loss the same day. And prescribing Ozempic off-label for weight loss rarely beats the system anymore — many plans now verify a diabetes diagnosis, and some ask prescribers to document lab results before approving refills. The practical rule: check coverage for the exact brand name tied to your diagnosis, not the drug family.
Medicare: A Legal Exclusion With One Wegovy Exception
Medicare is the strictest case. Federal law has excluded drugs used for weight loss alone from Part D coverage since the program was created, and as of July 2026 that exclusion still stands. Congress has debated lifting it for years; until it does, a prescription that says only “weight management” is not payable by Part D, no matter your BMI. If you are on Medicare and end up paying cash, our comparison of GLP-1 providers for adults over 60 covers the age-specific screening questions a good program should ask.
There are two real doors through the wall:
- Diabetes indications. Part D plans cover GLP-1s like Ozempic and Mounjaro when prescribed for type 2 diabetes, subject to each plan’s formulary and PA rules.
- The Wegovy heart-risk exception. In 2024, the FDA approved Wegovy for a second use: reducing the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease who also have obesity or overweight. Because that is a medical indication rather than weight loss, Part D plans have been permitted to cover Wegovy for those specific patients — generally with prior authorization proving the heart condition.
Medicare Advantage drug coverage follows the same Part D statute, so switching plan types does not escape the exclusion. If you are on Medicare, this is the fastest-moving rule on this page — confirm with your specific plan every year.
Medicaid and Marketplace Plans: A Patchwork
Medicaid coverage of weight-loss GLP-1s is decided state by state. A number of states cover Wegovy or Zepbound on their preferred drug lists with prior authorization; others exclude weight-loss drugs entirely; some have added, restricted, or dropped coverage as budgets shifted. There is no national answer — search your state’s Medicaid preferred drug list, or ask your prescriber’s office, which usually knows the local rules cold.
ACA marketplace plans behave like commercial plans without the employer: coverage varies by insurer and by metal tier, and weight-loss drug exclusions are common. The NIDDK’s guidance applies to every plan type here: talk with your provider about medication options and check what your specific plan covers before assuming anything.
How to Check Your GLP-1 Coverage in 5 Steps
You can get a near-certain answer in one sitting. Budget about 20 minutes.
- Pull up your plan’s formulary (drug list) — it is in your member portal, or ask member services to send it.
- Search the exact brand name. Look up Wegovy and Zepbound separately from Ozempic and Mounjaro. Seeing Ozempic listed does not mean weight-loss coverage exists.
- Read the flags next to the drug. “PA” means prior authorization, “ST” means step therapy, “QL” means quantity limits, and the tier number drives your copay.
- Call the number on your insurance card and ask four questions: Is Wegovy (or Zepbound) covered for weight management? What are the PA criteria? Is step therapy required? What will I pay per month after my deductible?
- Send the answers to your prescriber and ask them to file the PA with your BMI history, weight-related conditions, and prior weight-loss attempts attached.
Write down the date, the representative’s name, and a reference number for every call. If a denial comes later, that record helps.
How to Appeal a GLP-1 Denial
A PA denial is a first offer, not a verdict. Appeals succeed often enough that skipping them is leaving money on the table.
Start by requesting the denial reason in writing. Many denials are mechanical — a missing BMI reading, no documented diet history, a step-therapy box left unchecked — and refiling with complete records fixes them. Next, file an internal appeal with a letter of medical necessity from your prescriber tying your diagnosis to the plan’s own written criteria. Your denial letter states the deadline, commonly around 180 days. If the plan upholds its denial, most members can then request an external review, where an independent reviewer the plan does not control makes a binding decision. Your denial paperwork explains how to start it, and your state insurance department can help if the process stalls.
What You Will Pay With and Without Coverage
Coverage is worth fighting for because the cash gap is enormous. Here is the realistic 2026 landscape:
| Route | Typical monthly cost | Notes |
|---|---|---|
| Covered, after PA approval | Your plan’s copay or coinsurance | Varies by tier and deductible |
| Brand-name pens at retail, no coverage | Roughly $1,300+ | Per the cash prices we track |
| Manufacturer self-pay programs | Below retail, varies by dose | Direct-from-maker pens and vials |
| Compounded semaglutide via telehealth | About $99–$299 | Not FDA-approved |
Two honest notes on the cash lane. Compounded semaglutide is not FDA-approved, and the FDA has warned about dosing errors and adverse-event reports with unapproved GLP-1 versions — it is cheaper, not equivalent. And telehealth pricing has its own traps, like memberships and first-month teaser rates; our explainer on how telehealth weight loss works covers the process end to end. If insurance is off the table, start with our comparison of the cheapest online GLP-1 providers for verified cash prices, and see the full menu of ways to get GLP-1s without insurance — including manufacturer direct programs — before you commit to anything.